Illuminating the Druggable Genome Resource Dissemination and Outreach Center (IDG-RDOC)

照亮可药物基因组资源传播和外展中心 (IDG-RDOC)

• 批准号: 10314062
• 负责人: LARRY A. SKLAR
• 金额: $ 50万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-12-01 至 2023-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10314062
• 关键词: Adoption; Biocompatible Materials; Biological; Biological Assay; Biological Models; Biology; Biomedical Engineering; Chemicals; Collaborations; Collection; Communities; Community Outreach; Data; Data Science; Data Set; Development; Disease; Drug Targeting; Ecosystem; Education and Outreach; Experimental Models; Family; Flow Cytometry; Foundations; Funding; G-Protein-Coupled Receptors; Generations; Genome; Genomics; Guidelines; Human; Human Genome Project; Infrastructure; International; Investigation; Ion Channel; Laboratories; Medical; Molecular; Molecular Bank; Morphologic artifacts; New Mexico; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Policies; Process; Production; Protein Kinase; Proteins; Proteome; Protocols documentation; Publications; Reagent; Reporting; Reproducibility; Research; Research Personnel; Research Project Grants; Resolution; Resource Sharing; Resources; Services; System; Technology; Teleconferences; Terminology; Time; Training; Training Programs; Training and Education; United States National Institutes of Health; Universities; Work; clinical development; data exchange; data resource; data sharing networks; data standards; data tools; drug discovery; experience; genome resource; interoperability; meetings; member; metadata standards; novel; novel therapeutics; open innovation; operation; outreach; outreach program; pre-clinical; programs; repository; screening; small molecule; success; technology development; tool; training opportunity; web based interface; working group

PROJECT SUMMARY As the Human Genome Project (HGP) approached its successful conclusion, NIH was in the process of formulating the Roadmap, which evolved into the Common Fund. At the leading edge of these initiatives was the Biomedical Engineering Research Partnership (BRP), which promoted technology development. For the BRP, Sklar led the development of high throughput flow cytometry, a screening technology which transitioned into the Molecular Libraries Program (MLP), a logical successor to the HGP, to develop small molecule probes for newly discovered genomic targets. For the Common Fund, Illuminating the Druggable Genome (IDG) became the next logical successor to prioritize genomic targets for further investigation. The technology advanced via the BRP by Sklar became a foundation for the collaboration with Oprea resulting in 10 years of participation in the MLP through both pilot and production phases, with Sklar leading both administrative and laboratory efforts and Oprea leading the data science efforts. Toward the end of the MLP, Oprea, Sklar, and Schürer, who had also been part of the MLP since the pilot phase, joined forces for the BARD initiative (2012- 14) and again in Phase I (2015-17) and this Phase II IDG proposal (2018-24). Despite steady progress in developing novel therapeutics and their enormous medical and societal benefits, current drugs target only a small fraction of the human proteome. Even drugs in clinical development and most preclinical drug discovery research ignore a significant portion of the druggable proteome. Through the development, broad dissemination, and use of community scientific resources, the IDG program is focused on advancing research to study human proteins for which publicly available information or active research is currently lacking, in order to catalyze the discovery of novel biology with a particular focus on understudied members of the protein kinase, ion channel, and non-olfactory GPCR families. Our highly-coordinated team from the University of New Mexico and the University of Miami will establish the IDG Resource Dissemination and Outreach Center (RDOC) to facilitate widespread access to consortium- generated data and resources as well as to serve the overall administration of the IDG Consortium and its relationships with external partners. The IDG-RDOC will work with all IDG Consortium investigators to collect and curate information regarding critical tools and reagents being developed by the IDG Consortium and disseminate them through the IDG Portal. Specifically we will: (i) coordinate and support the IDG consortium via a highly experienced administrative team; (ii) facilitate and coordinate external partnerships, outreach, and training related to IDG program activities; and (iii) develop and implement data standards, policies, operations, and tools to collect, curate, identify, and disseminate IDG-generated resources in accordance with (extended) NIH FAIR (Findable, Accessible, Attributable, Interoperable, Reusable, Reproducible) principles. 1"

项目概要 随着人类基因组计划 (HGP) 接近成功，NIH 正在 制定路线图，该路线图后来演变为共同基金。这些举措的前沿是 生物医学工程研究合作伙伴关系（BRP），促进了技术发展。对于 BRP、Sklar 领导了高通量流式细胞术的开发，这是一种筛选技术， 进入分子图书馆计划 (MLP)（人类基因组计划的合理继承者），以开发小分子探针 用于新发现的基因组目标。为共同基金，阐明可药物基因组 (IDG) 成为优先考虑基因组目标以进行进一步研究的下一个逻辑继承者。技术 Sklar 通过 BRP 推进的项目成为与 Oprea 合作的基础，从而实现了 10 年的合作 通过试点和生产阶段参与 MLP，Sklar 负责管理和管理 实验室的努力和 Oprea 领导的数据科学工作。在 MLP 即将结束时，Oprea、Sklar 和 Schürer 自试点阶段起就加入了 MLP，并加入了 BARD 计划（2012 年- 14）以及第一阶段（2015-17）和第二阶段 IDG 提案（2018-24）。 尽管在开发新疗法及其巨大的医疗和社会效益方面取得了稳步进展， 目前的药物仅针对人类蛋白质组的一小部分。即使是处于临床开发阶段的药物和大多数药物 临床前药物发现研究忽略了可成药蛋白质组的很大一部分。通过 IDG 计划的重点是开发、广泛传播和使用社区科学资源 推进研究人类蛋白质的研究，这些蛋白质的公开信息或积极研究是 目前缺乏，以促进新生物学的发现，特别关注尚未充分研究的生物学 蛋白激酶、离子通道和非嗅觉 GPCR 家族的成员。 我们来自新墨西哥大学和迈阿密大学的高度协调的团队将建立 IDG 资源传播和外展中心 (RDOC) 旨在促进联盟的广泛访问 生成的数据和资源，并为 IDG 联盟及其联盟的整体管理服务 与外部合作伙伴的关系。 IDG-RDOC 将与所有 IDG 联盟调查人员合作收集 并整理有关 IDG 联盟正在开发的关键工具和试剂的信息，以及 通过 IDG 门户传播它们。具体来说，我们将： (i) 协调和支持 IDG 联盟 通过经验丰富的管理团队； (ii) 促进和协调外部伙伴关系、外展活动和 与 IDG 计划活动相关的培训； (iii) 制定和实施数据标准、政策、运营， 以及根据（扩展）收集、管理、识别和传播 IDG 生成的资源的工具 NIH FAIR（可查找、可访问、可归属、可互操作、可重用、可复制）原则。 1"